According to a new report, published by KBV research, The Global Genomics In Cancer Care Market size is expected to reach $53.5 billion by 2031, rising at a market growth of 15.7% CAGR during the forecast period.
The drug discovery & development segment is anticipating a CAGR of 16.4% during (2024 - 2031). The shift towards personalized medicine emphasizes the need for drugs tailored to individual genetic profiles. Genomic data allows for developing targeted therapies that address specific genetic mutations or biomarkers associated with a patient’s cancer. This personalized approach enhances drug efficacy and reduces side effects, driving demand for genomic-driven drug discovery. There is an increasing collaboration between academic institutions and the pharmaceutical industry in the field of cancer genomics.
The Instruments segment is leading the Global Genomics In Cancer Care Market by Product in 2023; thereby, achieving a market value of $27.1 billion by 2031. The rapid advancement in genomic technologies, such as next-generation sequencing (NGS), real-time PCR, and microarrays, has increased the demand for specialized instruments. These tools are essential for conducting high-throughput genomic analyses, understanding cancer genomics, and developing personalized treatment strategies.
The Genome Sequencing segment is registering a CAGR of 15.4% during (2024 - 2031). Genome sequencing provides comprehensive insights into the genetic makeup of cancer cells, identifying mutations, gene alterations, and other genomic features associated with cancer. This deep understanding is crucial for discovering new biomarkers, understanding cancer mechanisms, and developing targeted therapies, driving demand for genome sequencing technologies. Genome sequencing is often integrated with other omics data, such as transcriptomics, proteomics, and metabolomics, to provide a holistic view of cancer biology.
Full Report: https://www.kbvresearch.com/genomics-in-cancer-care-market/
The North America region dominated the Global Genomics In Cancer Care Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $18.7 billion by 2031. The Europe region is experiencing a CAGR of 15.5% during (2024 - 2031). Additionally, The Asia Pacific region would showcase a CAGR of 16.3% during (2024 - 2031).
By Application
By Product
By Technology
By Geography
Unique Offerings 
